NYSE

Bio-Rad Laboratories, Inc. Class A (BIO)

341 Thanks from members

Bio-Rad Laboratories (BIO) exhibits a mixed financial profile, balancing strong Q2 GAAP net income driven by its Sartorius AG investment and digital PCR momentum against flat currency-neutral revenue guidance and macro-driven Life Science segment declines.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →